Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumiliximab + FCR in Relapsed CLL (LUCID)
NCT00391066Phase 2Terminated
- Sponsor
- Biogen
- Start
- Nov 2006
- Primary completion
- Jul 2010
- Countries
- 23
01
Overview
Phase 2, randomised, open-label trial of lumiliximab in chronic lymphocytic leukemia (CLL) (2 arms), sponsored by Biogen. Primary endpoint: Complete Response rate at 33 weeks. Started Nov 2006; status: terminated.
02
Drugs
lumiliximab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00391066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00391066.